Apply to trial NCT06420973

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening